The rise of Viagra initially drove significant growth in the medicinal sector, creating a image of guaranteed profits. However, placing capital in companies solely reliant on blockbuster drugs like the erectile dysfunction pill presents considerable risks. Exclusive rights expiration has caused a

The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for revolutionary treatments and impressive returns